Overview

Safety, Tolerability of OP-724 in Patients With Primary Biliary Cholangitis (Phase I)

Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the safety and pharmacokinetics of OP-724 and to determine the recommended dose of OP-724 against Primary Biliary Cholangitis patients.
Phase:
Phase 1
Details
Lead Sponsor:
Kiminori Kimura, MD
Komagome Hospital
Collaborators:
Japan Agency for Medical Research and Development
Ohara Pharmaceutical Co., Ltd.